- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05891483
Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps
October 8, 2023 updated by: Guangdong Hengrui Pharmaceutical Co., Ltd
A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2 Efficacy and Safety Study of SHR-1905 in Patiens With Chronic Rhinosinusitis With Nasal Polyps
The study is being conducted to evaluate the efficacy, and safety of SHR-1905 injection in subjects with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to explore the reasonable dosage of SHR-1905 injection for CRSwNP.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
100
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Huize Han
- Phone Number: +0518-81220121
- Email: huize.han@hengrui.com
Study Locations
-
-
Shanghai
-
Shanghai, Shanghai, China, 200031
- Recruiting
- Eye & ENT Hospital of Fudan University
-
Principal Investigator:
- Dehui Wang
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Weight ≥40kg
- Diagnosed with chronic rhinosinusitis with nasal polyps (CRSwNP).
- Bilateral nasal polyps at screening and baseline, total NPS ≥5, ≥2 points for each nostril.
- NCS ≥2 at screening and baseline.
- SNOT-22≥20 at screening period and baseline.
- Recorded persistent NP symptoms for over 4 weeks prior to screening.
- Subjects received standard therapy with intranasal corticosteroids (INCS) and remained stable during the 4 weeks prior to randomization.
- NP surgery in the past and/or ACERS treated with SCS occurred within 2 years before randomization (or with contraindications/ intolerances).
Exclusion Criteria:
- Any comorbidities that may affect the efficacy evaluation of nasal polyps.
- Any comorbidities except for asthma that may affect blood EOS levels.
- Concomitant with immunodeficiency.
- Concomitant with contraindications or not suitable for nasal endoscopy.
- Uncontrolled hypertension.
- Uncontrolled diabetes.
- Infection within 2 weeks prior to screening to randomization that is clinically significant and/or should be treated with systemic antibiotics.
- Uncontrolled epistaxis within 4 weeks prior to randomization.
- Major surgery performed within 3 months prior to randomization, or surgery planned during the study, or treatments that may affect evaluations according to investigators.
- Parasitic infection within 6 months before randomization.
- Sinus or intranasal surgery (except for diagnostic biopsy) within 6 months prior to randomization, or changes in the nasal walls caused by sinus or intranasal surgery that made NPS evaluation impossible.
- Malignancies diagnosed within 5 years before randomization (except those with a low risk of metastasis or death).
- Abnormalities of laboratory tests at screening or baseline.
- Concomitant with active hepatitis B, positive hepatitis C virus antibodies, positive human immunodeficiency virus antibodies, or positive treponema pallidum antibodies.
- Prolonged QTc interval (>450ms for male and >470ms for female) or other clinically significant abnormal results of ECG at screening or baseline that may cause significant safety risks to subjects.
- FEV1 before the use of bronchodilator (pre-BD) was less than 50% at screening.
- Transfusion of blood products or immunoglobulin within 4 weeks prior to randomization.
- SCS or additional INCS use within 4 weeks before randomization, or planned use during treatment period.
- Regular use of decongestants (local or systemic) within 4 weeks before randomization, except for during the endoscopic procedure.
- Adnimistration of live vaccine or viral vector vaccine within 4 weeks before randomization.
- Allergen immunotherapy within 8 weeks before randomization.
- Smoking history ≥10 pack-years, smoking at screening, or smoking cessation less than 6 months at screening.
- Substance abuse, drug abuse, and/or excessive alcohol consumption within 1 year prior to randomization.
- Pregnancy (including positive pregnancy test at screening or baseline), lactation, or pregnancy plan during study period.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo Group
|
SHR-1905 Placebo Injection
|
Experimental: Treatment group A: SHR-1905 Injection(dose 1)
|
SHR-1905 Injection
|
Experimental: Treatment group B: SHR-1905 Injection(dose 2)
|
SHR-1905 Injection
|
Experimental: Treatment group C: SHR-1905 Injection(dose 3)
|
SHR-1905 Injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Nasal polyp scores (NPS)
Time Frame: Baseline to Week 24
|
Change from baseline in NPS at Week 24.
|
Baseline to Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
NPS
Time Frame: Baseline to Week 48
|
Changes from baseline in NPS from baseline at each evaluation time point.
|
Baseline to Week 48
|
Nasal Congestion Scores (NCS)
Time Frame: Baseline to Week 48
|
Changes from baseline in NCS at each evaluation time point.
|
Baseline to Week 48
|
Loss of smell
Time Frame: Baseline to Week 48
|
Changes from baseline in scores of loss of smell at each evaluation time point.
|
Baseline to Week 48
|
Runny nose/postnasal drip
Time Frame: Baseline to Week 48
|
Change from baseline in scores of runny nose/postnasal drip at each evaluation time point.
|
Baseline to Week 48
|
Facial pain and/or pressure
Time Frame: Baseline to Week 48
|
Change from baseline in facial pain and/or pressure scores at each evaluation time point.
|
Baseline to Week 48
|
Total symptoms score (TSS)
Time Frame: Baseline to Week 48
|
Changes from baseline in TSS each evaluation time point.
|
Baseline to Week 48
|
Sino-nasal outcome test-22 (SNOT-22) scores
Time Frame: Baseline to Week 48
|
Changes from baseline in SNOT-22 scores at each evaluation time point.
|
Baseline to Week 48
|
Proportion of subjects exposed to SCS for acute exacerbation of chronic rhinosinusitis (AECRS) over 24 weeks.
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
|
Dose of SCS used for AECRS over 24 weeks (converted to equivalent dose of prednisone).
Time Frame: Baseline to Week 24
|
Baseline to Week 24
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 4, 2023
Primary Completion (Estimated)
August 1, 2025
Study Completion (Estimated)
August 1, 2025
Study Registration Dates
First Submitted
May 25, 2023
First Submitted That Met QC Criteria
June 4, 2023
First Posted (Actual)
June 7, 2023
Study Record Updates
Last Update Posted (Actual)
October 11, 2023
Last Update Submitted That Met QC Criteria
October 8, 2023
Last Verified
May 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SHR-1905-202
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Rhinosinusitis With Nasal Polyps
-
Christiane HaaseActive, not recruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsDenmark
-
Ohio State UniversityActive, not recruitingChronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsUnited States
-
GB001, Inc, a wholly owned subsidiary of Gossamer...CompletedChronic Rhinosinusitis Without Nasal Polyps (CRSsNP) | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)United States, Czechia, Ukraine
-
St. Paul's Sinus CentreRecruitingAsthma | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal PolypsCanada
-
Johns Hopkins UniversityGlaxoSmithKlineRecruitingChronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal PolypsUnited States
-
Medical University of ViennaRecruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Nasal Polyps | Chronic Rhinosinusitis With Nasal PolypsAustria
-
Novartis PharmaceuticalsRecruitingChronic Rhinosinusitis With Nasal PolypsKorea, Republic of
-
University of California, San FranciscoNational Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health...RecruitingAsthma | Chronic Rhinosinusitis (Diagnosis) | Chronic Rhinosinusitis With Nasal PolypsUnited States
-
Johns Hopkins UniversityGenentech, Inc.RecruitingNasal Polyps | Chronic Rhinosinusitis With Nasal PolypsUnited States
-
AstraZenecaAmgenActive, not recruitingChronic Rhinosinusitis With Nasal PolypsUnited States, Canada, Denmark, Spain, United Kingdom, Germany, Hungary, China, Japan, Poland
Clinical Trials on SHR-1905 Injection
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Recruiting
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Recruiting
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Enrolling by invitationAdvanced Malignant TumorsChina
-
Shengjing HospitalJiangsu HengRui Medicine Co., Ltd.Not yet recruitingER Positive/HER2 Low Breast CancerChina
-
Guangdong Hengrui Pharmaceutical Co., LtdCompleted
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
Henan Cancer HospitalRecruitingHER2 Low Breast CarcinomaChina
-
Jiangsu HengRui Medicine Co., Ltd.Not yet recruitingNasopharyngeal CarcinomaChina
-
Beijing Suncadia Pharmaceuticals Co., LtdNot yet recruiting